Medicine guide
Glybera
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Alipogene tiparvovec
- Made by
- uniQure biopharma B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
Details
| Made by | uniQure biopharma B.V. |
|---|---|
| Active substance | Alipogene tiparvovec |
| Used in | Heart, blood pressure and circulation |
| Classification | C10AX10 · Heart, blood pressure and circulation |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2012-10-25 |
| Last updated by the regulator | 2017-10-30 |
| EMA product number | EMEA/H/C/002145 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).